EPHA2 Knockout HEK293 Cell Line

EPHA2 Knockout HEK293 Cell Line
Cat.No.:

EDC07552

Species:

Human

Cell Name:

HEK293

Gene:

EPHA2

Gene ID:

1969

Size:

1×10⁶cells

EPHA2 Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
Cat.No. EDC07552
Product Name EPHA2 Knockout Cell Line (HEK 293)
Cell Line HEK293
Cellosaurus ID CVCL_0045
Cell Line Synonyms Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293
Gene EPHA2
NCBI Gene ID
Gene Synonyms ARCC2|CTPA|CTPP1|CTRCT6|ECK
Summary
This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. Mutations in this gene are the cause of certain genetically-related cataract disorders.[provided by RefSeq, May 2010]
Associated Diseases Non-tumor
Morphology Adherent
Passage Ratio 1/5,2days
Complete Culture Medium DMEM + 10% FBS
Freezing Medium 95% Complete culture medium+ 5% DMSO
QC Indels validated by Sanger sequencing; sterility confirmed via microbial testing.
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
LociSTR Info (Sample Cell)
Sample Cell Line: HEK293
STR Info (Cell bank)
Cell Line: HEK293
Allele1Allele2Allele1Allele2
Amelogenin X X
CSF1P0 12 11 12
D2S1338 19 19
D3S1358 15 17 15 17
D5S818 8 8 9
D7S820 11 12 11 12
D8S1179 12 14 12 14
D13S317 12 14 12 14
D16S539 9 13 9 13
D18S51 17 18 17 18
D19S433 15 18 15 18
D21S11 28 30.2 28 30.2
FGA 23 23
Penta D 9 10 9 10
Penta E 7 15 7 15
TH01 7 9.3 7 9.3
TPOX 11 11
vWA 16 19 16 19
D6S1043 11 11
D12S391 19 21 11 15
D2S441 11 15 11 15
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.

FAQ

The choice depends on whether you are studying EPHA2's role as a class A Eph family RTK or modeling its functions in cancer biology and emerging EPHA2-targeted therapeutic strategies. The Knockout line is the standard tool for asking whether EPHA2 is required for these processes — EPHA2 is the most-characterized EphA subfamily receptor with established roles in tumor angiogenesis, cancer cell migration, and emerging functions as a cancer therapy target; EPHA2 binds ephrin-A1 with high affinity, and EPHA2 overexpression correlates with poor prognosis in multiple cancers. Overexpression is useful for studying EPHA2 gain-of-function effects. For cancer biology research, the EDITGENE EPHA2 Knockout in HEK293 is a workhorse mechanistic platform — HEK293 supports systematic structure-function studies. Rescue with wild-type or kinase-dead EPHA2 is the standard specificity control. The knockout is a critical specificity tool for anti-EPHA2 antibodies, EPHA2-targeted ADCs, and emerging Eph-targeted cancer therapeutics — EPHA2 has been explored as a target for ADC development in multiple cancer types.
Primary applications: • Ephrin-A1 binding and signaling: ephrin-A1-Fc stimulation followed by phospho-EPHA2 (Y594, Y772) Western blot analysis. • Cancer biology: cell migration, invasion, and angiogenesis assays given EPHA2's emerging cancer roles. • EPHA2-targeted ADC specificity: critical genetic control for anti-EPHA2 antibody-drug conjugates in cancer drug development. • EphA family dissection: parallel analysis with EPHA6 Knockout in HAP1 (also available) for cross-subfamily characterization. EDITGENE recommends this HEK293-based model for biochemical EPHA2 research and structure-function studies.
Yes. EPHA2 rescue experiments are well-established for cancer research: • Construct design: use a codon-modified EPHA2 sequence with a small intracellular C-terminal tag (FLAG, HA). EPHA2 has the canonical Eph architecture — preserve all elements. • Surface localization validation: confirm plasma membrane localization before ephrin-A binding studies. • Kinase-dead rescue: K646A mutation in the ATP-binding lysine abolishes catalytic activity. • Functional readout: rescue should restore ephrin-A1-induced phospho-EPHA2 (Y594, Y772) and downstream signaling. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.

Required Accessories

Related Products

Flash CRISPR Knockout Kit(Universal Version)Flash CRISPR Knockout Kit(Universal Version)
Flash-Pro CRISPR KO Kit (For Organoids / Stem Cells)Flash-Pro CRISPR KO Kit (For Organoids / Stem Cells)

Related Services

Knockout Cell LineKnockout Cell Line
Contact Us
*
*
*
*
How did you hear about us: